NCT05877651View on ClinicalTrials.gov

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

October 15, 2021

Study Completion Date

October 15, 2021

Conditions

Solid Tumors

Interventions

BIOLOGICAL

MASCT-I injection

The final products of MASCT-I technology are dendritic cells (DC) and effector T cells

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors

Lead Sponsor

HRYZ Biotech Co.

All Listed Sponsors

lead

HRYZ Biotech Co.

INDUSTRY

NCT05877651 - MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. | Biotech Hunter | Biotech Hunter